The xF+ Liquid Biopsy Panel is a non-invasive testing solution that utilizes ctDNA sequencing to evaluate up to 523 genes specifically tailored for identifying actionable variants in solid tumors. Developed for comprehensive genetic profiling, this panel excels in detecting circulating tumor DNA elements in blood samples, offering a vital complement to tissue-based genotyping in certain cancer types. It includes enhanced regions for deeper sequencing accuracy and delivers results on genomic mutations such as SNVs, insertions/deletions, and CNVs, along with oncological markers like MSI-H and bTMB. This depth of analysis provides clinicians with critical information about a tumor's genetic landscape, which aids in personalizing treatment strategies and monitoring disease progression non-invasively.
